Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 13, 2021 (5 years ago)

Dry Eye Test (Fluorescein Sodium)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Dry Eye Test, Fluorescein Sodium, Ophthalmic Strips USP (0.12mg Fluorescein Sodium), 100 Sterile Strips (50 Pouches of 2 Strips Each), Manufactured by: Nomax, Inc, St. Louis, MO 63123, NDC: 51801-008-15

Affected NDC 51801-0008-15

Compare with the code on your package — it is the most precise check available.

Drug: Fluorescein Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dry Eye Test
Fluorescein Sodium
NDC 51801-0008
.12 mg/1 Strip
Ophthalmic
Nomax Inc. Rx
Recalling firm
Nomax Inc
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0387-2021 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Fluorescein recalls

See all
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-404-01 D-0465-2024

Other recalls by Nomax Inc

All 2021 recalls
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-404-01 D-0465-2024
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-403-03 D-0464-2024
Class II · Moderate risk

GloStrips

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 51801-009-40 D-0463-2024
Class II · Moderate risk

GloStrips

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 51801-003-40 D-0462-2024